Market closedNon-fractional
Sage Therapeutics/SAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Ticker
SAGE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
487
Website
www.sagerx.com
SAGE Metrics
BasicAdvanced
$630M
Market cap
-
P/E ratio
-$8.39
EPS
0.92
Beta
-
Dividend rate
Price and volume
Market cap
$630M
Beta
0.92
Financial strength
Current ratio
12.224
Quick ratio
11.772
Total debt to equity
0.468
Management effectiveness
Return on assets (TTM)
-31.98%
Return on equity (TTM)
-54.72%
Valuation
Price to revenue (TTM)
6.893
Price to book
0.9
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
-1.477
Growth
Revenue change (TTM)
868.96%
Earnings per share change (TTM)
-10.49%
3-year revenue growth (CAGR)
-56.59%
3-year earnings per share growth (CAGR)
-10.38%
What the Analysts think about SAGE
Analyst Ratings
Majority rating from 22 analysts.
SAGE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.9M
-89.86%
Net income
-$108M
231.50%
Profit margin
-1,372.15%
3,169.36%
SAGE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.68
-$3.37
-$0.55
-$1.80
-
Expected
-$2.55
-$2.73
-$1.28
-$1.65
-$1.66
Surprise
4.95%
23.42%
-56.94%
9.28%
-
SAGE News
AllArticlesVideos
Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue
Accesswire·6 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
GlobeNewsWire·10 hours ago
Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue
Accesswire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sage Therapeutics stock?
Sage Therapeutics (SAGE) has a market cap of $630M as of July 27, 2024.
What is the P/E ratio for Sage Therapeutics stock?
The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of July 27, 2024.
Does Sage Therapeutics stock pay dividends?
No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Sage Therapeutics dividend payment date?
Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sage Therapeutics?
Sage Therapeutics (SAGE) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Sage Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.